This company is no longer active
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Vallon Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.40 |
| 52 Week High | US$2.17 |
| 52 Week Low | US$0.21 |
| Beta | -1.15 |
| 1 Month Change | -0.52% |
| 3 Month Change | 39.13% |
| 1 Year Change | -82.38% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| VLON | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 10.5% | -2.3% | -3.7% |
| 1Y | -82.4% | 11.4% | 20.2% |
Return vs Industry: VLON underperformed the US Pharmaceuticals industry which returned 2.6% over the past year.
Return vs Market: VLON underperformed the US Market which returned -5.3% over the past year.
Price Volatility
| VLON volatility | |
|---|---|
| VLON Average Weekly Movement | 42.9% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VLON's share price has been volatile over the past 3 months.
Volatility Over Time: VLON's weekly volatility has increased from 29% to 43% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 2 | n/a | www.vallon-pharma.com |
As of April 21, 2023, Vallon Pharmaceuticals, Inc. was acquired by GRI Bio, Inc., in a reverse merger transaction. Vallon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. The company’s lead investigational product candidate is ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy.
Vallon Pharmaceuticals, Inc. Fundamentals Summary
| VLON fundamental statistics | |
|---|---|
| Market cap | US$5.39m |
| Earnings (TTM) | -US$7.02m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs VLON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VLON income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.02m |
| Earnings | -US$7.02m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VLON perform over the long term?
See historical performance and comparison